# Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

> **NCT05422183** · PHASE2 · UNKNOWN · sponsor: **Zhongda Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Cancer, Epithelial

## Interventions

- **DRUG:** Envafolimab
- **DRUG:** Lenvatinib
- **DRUG:** VP-16

## Key facts

- **NCT ID:** NCT05422183
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-30
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422183, "Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05422183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*